中
Home
About TUL
Group Introduction
Executive Directors
Subsidiaries
Contact Us
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
News
TUL Highlights
Product Center
Finished Products
Comprehensive Health Products
APIs and Intermediates
Animal protection products
Empty capsule
Medical device
Cosmetic Peptide Series
Sustainability
Enhancing Governance
Normalizing Healthiness
Brand Building
People-Oriented
Green Development
ESG Reports
ESG News
Investor Relations
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
2026-07-15
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION
Learn More
2026-07-03
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT TADALAFIL TABLETS
Learn More
2026-06-12
APPROVAL FOR CLINICAL TRIAL OF THE GROUP’S PRODUCT TUL321 CAPSULES
Learn More
2026-05-20
APPROVAL FOR CLINICAL TRIAL OF GROUP’S PRODUCT TUL108 FOR INJECTION
Learn More
2026-05-08
APPROVAL FOR CLINICAL TRIAL OF GROUP’S PRODUCT UBT38006 INJECTION
Learn More
All News
Select Year
2026
2025
2024
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION
2026-07-15
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT TADALAFIL TABLETS
2026-07-03
APPROVAL FOR CLINICAL TRIAL OF THE GROUP’S PRODUCT TUL321 CAPSULES
2026-06-12
APPROVAL FOR CLINICAL TRIAL OF GROUP’S PRODUCT TUL108 FOR INJECTION
2026-05-20
APPROVAL FOR CLINICAL TRIAL OF GROUP’S PRODUCT UBT38006 INJECTION
2026-05-08
FDA APPROVAL OF IND FOR GROUP’S PRODUCT TUL321 CAPSULES
2026-04-29
APPROVAL FOR CLINICAL TRIAL OF THE GROUP’S PRODUCT DUPILUMAB INJECTION
2026-04-23
Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
2026-03-26
APPROVAL FOR MARKETING OF THE GROUP'S PRODUCT INSULIN DEGLUDEC INJECTION
2026-03-10
Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
2026-02-25
THE GROUP’S PRODUCT ROXITHROMYCIN CAPSULES PASSED THE CONSISTENCY EVALUATION
2026-02-10
APPROVAL FOR CLINICAL TRIAL OF UBT251 INJECTION ON INDICATION OF OSA
2026-02-04
Prev
1
2
3
Next
WeChat
Official
Account
To Top
粤公网安备44040402000348号
